ASH 2021 | Pembrolizumab plus vorinostat in patients with Hodgkin lymphoma refractory to prior PD-1 blockade
Alex Herrera
• 13 Dec 2021
Alex Herrera, MD, City of Hope, Duarte, CA, discusses a Phase I study evaluating the safety and efficacy of pembrolizumab plus vorinostat, a histone deacetylase inhibitor, in patients with relapsed/refractory (R/R) Hodgkin lymphoma. Dr Herrera shares that the overall response rate (ORR) and complete response (CR) rate were good, particularly in patients who were refractory to prior PD1 blockade, including patients who had progressed while receiving PD1 blockade as their most recent therapy. The study demonstrated that histone deacetylase inhibition could potentially resensitize patients with Hodgkin lymphoma to PD1 blockade. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
